hPCSK9
Nomenclature
C57BL/6JSmo-Pcsk9tm2(hPCSK9)/Smoc
Cat. NO.
NM-HU-00075
Strain State
Repository Live
Gene Summary
Gene Symbol
Pcsk9
Model Description
Validation Data
Fig.1 Detection of human PCSK9 expression in serum of WT C57BL/6 mice and HO hPCSK9 mice by ELISA (n=7 in hPCSK9 group, male).
Abbr. HO, homozygous; WT, wild type.
Fig.2 Detection of mouse PCSK9 expression in serum of WT C57BL/6 mice and HO hPCSK9 mice by ELISA. Mouse PCSK9 was exclusively detectable in wild-type C57BL/6 mice. Serum were collected from wild-type C57BL/6 mice (n=3, male, 6 weeks old) and HO hPCSK9 mice (n=3), and analyzed by ELISA.
Abbr. HO, homozygous; WT, wild type; N.D. not dected.
Fig.3 Detection of the blood lipid index of (A) TG, (B) TC, (C) HDL-C and (D) LDL-C in chow diet-fed WT mice and HO hPCSK9 mice before treatment. (n=7-8, 6-week-old male mice).
Abbr. WT, wild type; HO, Homozygous; CD, chow diet.
Fig.4 Body weight in chow diet-fed and Evolocumab-treated HO hPCSK9 knockin mice (8 male mice in each group).
Abbr. HO, Homozygous; CD, chow diet.
Fig.5 Detection of the blood lipid index of (A) TG, (B) T-CHO, (C) HDL-C and (D) LDL-C in chow diet-fed and Evolocumab-treated HO hPCSK9 knockin mice.
Blood lipids level of hPCSK9 mice before and after dosing were detected. Data were all normalized to control (8 male mice in each group. Mean ± SEM. *p < 0.05 and **p < 0.01 in Evolocumab group under t-test versus control).
Abbr. HO, Homozygous; CD, chow diet.
Fig.6 Liver weight-to-body weight ratio in chow diet-fed HO hPCSK9 knockin mice after 35 days of dosing (8 male mice in each group).
Abbr. HO, Homozygous; CD, chow diet.
Fig.7 Liver LDLR concentration in chow diet-fed HO hPCSK9 knockin mice after 35 days of dosing (8 male mice in each group, Mean±SEM, t-test, *p<0.05).
Abbr. HO, Homozygous; CD, chow diet.
Publications 1piece
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
